Cheryl Arrowsmith is the Chief Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a multinational public-private partnership that supports the discovery of new medicines through protein-based open access research. She leads the SGC’s program to develop chemical probes to chromatin regulators for target validation. Cheryl is also Sr. Scientist at Princess Margaret Cancer Centre in Toronto. Her current research interests focus on structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer.